Navigation Links
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
Date:7/30/2013

clude assessment of the safety of MYDICAR by determining the incidence and severity of adverse events and changes in laboratory parameters. Safety evaluations include the incidence and severity of all adverse events (including procedure-related), summaries of concomitant medications, vital signs, physical exams, implantable cardioverter defibrillator (ICD) interrogations and laboratory parameters, and the time to cardiovascular-related death.

About Celladon
Celladon is a privately held clinical stage biotechnology company committed to applying our first-mover, leadership position in the field of SERCA enzymes to transform the lives of patients with important, life-threatening diseases. SERCA's are a family of enzymes relevant to regulating intra-cellular calcium in all human cells. In turn, cellular calcium levels and calcium dysregulation plays a crucial role in a number of important and complex medical conditions and diseases such as heart failure, PAH, diabetes and Alzheimer's disease. Our singular focus is to apply our scientific leadership position to develop gene therapies and small molecules for these complications and we believe Celladon is a first mover in this emerging field. Our lead development program MYDICAR is currently under investigation in an international 200 patient Phase 2b clinical trial in advanced heart failure.

Further information can be found at www.celladon.net.



'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
8. Neogen Corporation Announces 2nd Quarter Results Conference Call
9. Luminex Corporation to Present at JP Morgan Healthcare Conference
10. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
11. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... development of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has ... to commence in Europe. - ...
... 20 The MattsonJack Group, Inc.,(MattsonJack), is pleased ... M.P.H. to Medical Director for MattsonJack. (Photo: ... in September 2000 as a consultant and,Assistant Medical ... the,University of Missouri -- Kansas City. He subsequently ...
... The Chrome Group today announced its,plans to seek ... on trading,platforms in Europe and the Middle East. In ... Officer, Mr. Val Oji said that "this,was part of ... the next two years. Chrome recently signed a Memorandum,of ...
Cached Biology Technology:YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... DALLAS Nov. 16, 2009 As the number of ... "swine flu," continues to rise, researchers have been scrambling to ... lower than expected in older adults. In ... Proceedings of the National Academy of Sciences , a ...
... With 900,000 assisted reproduction treatments annually such as ... to screen both partners before each treatment could lead ... figures do not include the additional overhead costs such ... have to carry on top of that. The new ...
... been awarded nearly $3 million in federal stimulus funds ... Lindsay and Paul Westerhoff will lead a pair of ... fields of rapid DNA sequencing and the potential health ... & Reinvestment Act of 2009 ("Recovery Act" or "ARRA"), ...
Cached Biology News:UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 2UT Southwestern scientist begins to unravel what makes pandemic H1N1 tick 3Statement of ESHRE on the European Commission proposal of viral screening 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 2ASU research efforts to improve human health will get $3 million in federal stimulus grants 3
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... Ideal for biocompatibility testing at ... circulation of air through a clean ... internal temperature up to 140F. Transparent ... strip shields allow easy access to ...
... Note: Protein determined by Biuret. ... M (NH 4 ) 2 ... Preparation Note: Affinity purified • ... • Additives: MgCl 2 1 ...
Biology Products: